Human embryonic stem cells: caught between a ROCK inhibitor and a hard place.
Since their derivation, human embryonic stem (hES) cells have been used for a variety of applications including developmental biology, pathology, chemical biology, genomics, and proteomics. However, their most important potential application is the generation of cells and tissues, which can be used for cell-based therapies. One of the main drawbacks of hES cell culture is that they are particularly sensitive to dissociation, which is required for passaging, expansion, cryopreservation, and other applications. Recently, it has been discovered that an inhibitor of Rho kinase (ROCKi; Y-27632) increases the survival rate of dissociated, single hES cells. This breakthrough has allowed new methods in hES cell culture to be developed, with the promise of increasing hES cell numbers into the realm of clinical relevance. In our studies demonstrating that ROCKi dramatically increases hES cell cryopreservation efficiency, we have observed that ROCKi treatment does not decrease hES cell's susceptibility to apoptosis. Rather, we hypothesize that ROCKi treatment desensitizes single hES cells to their environment reducing the odds that individual cells will undergo anoikis.
Krawetz
Roman J
RJ
University of Calgary, Calgary, Alberta, Canada.
Li
Xiangyun
X
Rancourt
Derrick E
DE
D017209:Apoptosis; D053595:Embryonic Stem Cells / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology*; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D015398:Signal Transduction; D054460:rho-Associated Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
D047428:Protein Kinase Inhibitors; D054460:rho-Associated Kinases